Covidien recalls device linked to 3 deaths during thoracic surgery

Covidien ($COV) announced Monday that it is conducting a voluntary recall of all production lots for the Duet TRS with respect to use in the thoracic cavity after reports of 13 serious injuries and three deaths.

The Duet TRS includes a fully integrated tissue reinforcement system to support staple lines in tissues. Since its launch in 2009, more than 500,000 units have been sold worldwide.

The company says it is working with the FDA and other regulatory bodies to modify instructions for use to contraindicate the device in thoracic procedures. It also has placed a hold on its Duet TRS inventory to allow for the relabeling with new instructions for use. "These steps are consistent with our belief that patient safety is a commitment that cannot be compromised," said Bryan Hanson, Covidien surgical solutions group president, in a statement. "Patient safety is our first obligation."

Covidien says about one-third of procedures using the device are for thoracic indications. However, the device will still be used for other indications, including abdominal procedures.

- see the Covidien release

Suggested Articles

The AI-based drug molecule designer XtalPi has secured a mammoth funding round totaling $318.8 million, from global banking and tech investors.

LabCorp has licensed a blood test from Genfit designed to identify patients with risky cases of the liver disease NASH.

Philips has launched a compact, single-use device for physically clearing potentially dangerous blood clots lodged in the arms and legs.